Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305162 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
A Phase 3 study, sponsored by The Medicines Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8,882
- Enrollment target
NCT00305162: Clinical Trial Phase 3 study, sponsored by The Medicines Company.
NCT00305162 is a Phase 3 study that was terminated before completion, run by The Medicines Company. The registered enrollment target is 8,882 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1052% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305162, a Phase 3 study, was terminated before completion, sponsored by The Medicines Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8,882 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
Primary Outcome
(composite incidence)
Interventions
- DRUG Placebo bolus & placebo infusion
- DRUG Placebo capsules - end of infusion
- DRUG Cangrelor (P2Y12 inhibitor)
- DRUG clopidogrel (oral P2Y12 inhibitor)
- DRUG Placebo capsules - as soon as possible after randomization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,882 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Why NCT00305162 stopped before completion
NCT00305162 is an interventional study that assigns participants to a tested intervention. Its 8,882 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1052% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo bolus & placebo infusion is the first listed.
NCT00305162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00305162 about?
NCT00305162 is a clinical study titled "A Clinical Trial to Demonstrate the Efficacy of Cangrelor". The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
What is the current status of trial NCT00305162?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8,882 participants. The study started on 2006-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00305162?
The interventions under investigation include: Placebo bolus & placebo infusion (DRUG), Placebo capsules - end of infusion (DRUG), Cangrelor (P2Y12 inhibitor) (DRUG), clopidogrel (oral P2Y12 inhibitor) (DRUG), Placebo capsules - as soon as possible after randomization (DRUG).
Who is sponsoring clinical trial NCT00305162?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00305162's enrollment target sits among peer trials
8,882 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia